Clinical Study for Mongolian Medicine Dedu Honghua Qiwei Powder in the Treatment of Liver Fibrosis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800020394

Enrollment

Unknown

Registered

2018-12-28

Start date

2019-01-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis

Interventions

Mongolian medicine group:Oral with Mongolian Medicine Dedu Honghua Qiwei Powder

Chinese medicine group:Oral compound armor soft liver tablets

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet both diagnostic criteria of Mongolia medicine and conventional medicine; 2. Liver perforation liver fibrosis stage F < 2, and ALT < 2ULN (upper limit of normal) 3. Aged 18 to 65 years old male and female; 4. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Combine other hepadnavirus infections, drug-induced liver damage, and autoimmune liver disease; 2. Chronic severe hepatitis, decompensated cirrhosis, liver tumor patients; 3. Patients with severe diseases of the lungs, heart, kidneys, and gastrointestinal tract or mental patients; 4. Pregnant or lactating women; 5. taking nucleoside antiviral drugs, anti-fibrosis treatment was given within 6 months; do not follow the prescribed medication or incomplete data, etc., affect the efficacy or safety judgment.

Design outcomes

Primary

Measure	Time frame
Liver function index;	—

Countries

China

Contacts

Public ContactBAOLIDAO

Affiliated Hospital of Inner Mongolia Medical University

baolidao237@163.com+86 0471 3451717

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026